Predict your next investment

SPI Pharma company logo
HEALTHCARE | Drug Development
spipharma.com

See what CB Insights has to offer

About SPI Pharma

SPI Pharma supplies engineered products and solutions that improve the formulation and delivery of drug products to meet patient needs to the pharmaceutical industry. It is based in Wilmington, Delaware.

SPI Pharma Headquarter Location

503 Carr Road 2nd Floor

Wilmington, Delaware, 19809,

United States

Latest SPI Pharma News

SPI launches UltraBurst excipient designed for ODT formulation

Aug 18, 2021

By Jenni Spinner The pjarmaceutical excipient, intended for use in the formulation of flash orally dissolving tablets, is designed to disintegrate in less than 10 seconds. SPI Pharma has announced the introduction of UltraBurst, an excipient platform intended for flash orally disintegrating tablets (ODTs). According to the manufacturer, the use of the excipient in an ODT facilitates the disintegration of a tablet in under 10 seconds. Graeme Macleod, global manager of R&D for SPI Pharma, said proper formulation of flash ODTs can be tricky but possibly with the right excipient. “Achieving content uniformity for low-dose micronized actives requires understanding of the API ​[active pharmaceutical ingredient] characteristics and how these interact with the excipient platform​,” he said. “Larger tablets and tablets with higher drug loadings can be challenging as achieving faster disintegration times becomes more difficult as the tablet size increases or API properties mask the functionality of the excipient platform—fortunately, UltraBurst is designed to overcome these challenges as it relies on multiple mechanisms to promote tablet disintegration​.” According to Macleod, UltraBurst offers excellent flow properties and is suited for direct compression processes. Further, he said, it can be used to generate robust tablets with low friability that withstand further downstream processing, and the resulting tablets do not need specialized protective packaging. John McInerney, general manager of SPI Pharma’s excipients and drug delivery systems business unit, said UltraBurst performs favorably compared to similar products currently offered by other companies. “Across a wide range of different API loadings and tablet sizes, we can demonstrate a significant reduction in disintegration time against the current market alternatives​,” McInerney said. “We see reductions in disintegration times between 20-40% without loss of tablet hardness or increased friability. "​ Macleod commented that UltraBurst offers improved disintegration times for both small- and large-format tablets. “Examples include disintegration times in the 4-9 second range for smaller (50-200mg) tablets, compared with 12-15 seconds​,” Macleod reported. “For larger tablets (500mg) we have seen disintegration times reduce from 80-90 secs with conventional ODT platforms to 12 seconds with UltraBurst​.” Macleod added SPI Pharma offers resources to help companies interested in working with UltraBurst or other ODT-geared excipients. “We have a Pharmasolutions business that is built on our formulation and analytical knowledge and capability; we offer a flexible approach to working with customers and can produce full data packages of new dose forms (eg ODTs, taste masking, softgel capsules, lozenges, etc.) for generic APIs,​” he said. “We will also work with customers and partners on proof of concept development, or partial stability and/or formulation projects​.” Orally disintegrating tablets appeal to patients and developers in large part due to various patient-friendly features. They do not require water, accommodate patients with difficulty swallowing, are manageable for pediatric patients, and generally help improve adherence. Copyright - Unless otherwise stated all contents of this web site are © 2021 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

SPI Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SPI Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.